BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petersen CT, Krenciute G. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma. Front Oncol 2019;9:69. [PMID: 30863720 DOI: 10.3389/fonc.2019.00069] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung JG, Le A. Metabolism of Immune Cells in the Tumor Microenvironment. Adv Exp Med Biol 2021;1311:173-85. [PMID: 34014543 DOI: 10.1007/978-3-030-65768-0_13] [Reference Citation Analysis]
2 Venetis K, Invernizzi M, Sajjadi E, Curigliano G, Fusco N. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treat Rev 2020;90:102089. [PMID: 32889360 DOI: 10.1016/j.ctrv.2020.102089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Wang W, Li H, Zhang L, Jiang W, Shen L, Fan G. Clinical applications of monitoring immune status with 90 immune cell subsets in human whole blood by 10-color flow cytometry. Int J Lab Hematol 2021. [PMID: 33870648 DOI: 10.1111/ijlh.13541] [Reference Citation Analysis]
4 Krishna D, Rittié L, Tran H, Zheng X, Chen-Rogers CE, McGillivray A, Clay T, Ketkar A, Tarnowski J. Short Time to Market and Forward Planning Will Enable Cell Therapies to Deliver R&D Pipeline Value. Hum Gene Ther 2021;32:433-45. [PMID: 33023309 DOI: 10.1089/hum.2020.212] [Reference Citation Analysis]
5 Giotta Lucifero A, Luzzi S. Emerging immune-based technologies for high-grade gliomas. Expert Rev Anticancer Ther 2022. [PMID: 35924820 DOI: 10.1080/14737140.2022.2110072] [Reference Citation Analysis]
6 Hernández-López A, Téllez-González MA, Mondragón-Terán P, Meneses-Acosta A. Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Front Pharmacol 2021;12:720692. [PMID: 34489708 DOI: 10.3389/fphar.2021.720692] [Reference Citation Analysis]
7 Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI, Sang QA. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy. J Cancer 2021;12:6949-63. [PMID: 34729098 DOI: 10.7150/jca.64205] [Reference Citation Analysis]
8 Feldman L, Brown C, Badie B. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. Neuromolecular Med 2021. [PMID: 34665390 DOI: 10.1007/s12017-021-08689-5] [Reference Citation Analysis]
9 Seyedmirzaei H, Keshavarz-Fathi M, Razi S, Gity M, Rezaei N. Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2). J Oncol Pharm Pract 2021;27:1235-44. [PMID: 33530866 DOI: 10.1177/1078155221991636] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Terry RL, Meyran D, Fleuren EDG, Mayoh C, Zhu J, Omer N, Ziegler DS, Haber M, Darcy PK, Trapani JA, Neeson PJ, Ekert PG. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers (Basel) 2021;13:4704. [PMID: 34572932 DOI: 10.3390/cancers13184704] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M. The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology. Int J Mol Sci 2019;20:E2810. [PMID: 31181772 DOI: 10.3390/ijms20112810] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
12 Krug A, Martinez-Turtos A, Verhoeyen E. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. Cancers (Basel) 2021;14:183. [PMID: 35008348 DOI: 10.3390/cancers14010183] [Reference Citation Analysis]
13 Zhang Y, Guan XY, Jiang P. Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors. Front Immunol 2020;11:594609. [PMID: 33381115 DOI: 10.3389/fimmu.2020.594609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
14 Morales L, Paramio JM. Cell Therapies in Bladder Cancer Management. Int J Mol Sci 2021;22:2818. [PMID: 33802203 DOI: 10.3390/ijms22062818] [Reference Citation Analysis]
15 Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer 2019;7:258. [PMID: 31619289 DOI: 10.1186/s40425-019-0741-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
16 Giotta Lucifero A, Luzzi S. Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). Brain Sci 2021;11:386. [PMID: 33803885 DOI: 10.3390/brainsci11030386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sertkaya H, Ficarelli M, Sweeney NP, Parker H, Vink CA, Swanson CM. HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency. Sci Rep 2021;11:12067. [PMID: 34103612 DOI: 10.1038/s41598-021-91309-w] [Reference Citation Analysis]
18 Greenfield AL, Hauser SL. Nucleic Acid-Based Therapeutics Relevant to Neuroimmune Conditions. Neurotherapeutics 2019;16:314-8. [PMID: 31087242 DOI: 10.1007/s13311-019-00740-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Altshuler DB, Kadiyala P, Nuñez FJ, Nuñez FM, Carney S, Alghamri MS, Garcia-Fabiani MB, Asad AS, Nicola Candia AJ, Candolfi M, Lahann J, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. Prospects of biological and synthetic pharmacotherapies for glioblastoma. Expert Opin Biol Ther 2020;20:305-17. [PMID: 31959027 DOI: 10.1080/14712598.2020.1713085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chow DS, Khatri D, Chang PD, Zlochower A, Boockvar JA, Filippi CG. Updates on Deep Learning and Glioma. Neuroimaging Clinics of North America 2020;30:493-503. [DOI: 10.1016/j.nic.2020.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Locoregional delivery of CAR-T cells in the clinic. Pharmacol Res 2022;182:106329. [PMID: 35772645 DOI: 10.1016/j.phrs.2022.106329] [Reference Citation Analysis]
22 Barish ME, Weng L, Awabdeh D, Zhai Y, Starr R, D'apuzzo M, Rockne RC, Li H, Badie B, Forman SJ, Brown CE. Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. Neoplasia 2022;30:100801. [DOI: 10.1016/j.neo.2022.100801] [Reference Citation Analysis]
23 Oprita A, Baloi SC, Staicu GA, Alexandru O, Tache DE, Danoiu S, Micu ES, Sevastre AS. Updated Insights on EGFR Signaling Pathways in Glioma. Int J Mol Sci 2021;22:E587. [PMID: 33435537 DOI: 10.3390/ijms22020587] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
24 Tian Y, Ke YQ, Ma Y. Immune-Related lncRNA Correlated with Transcription Factors Provide Strong Prognostic Prediction in Gliomas. J Oncol 2020;2020:2319194. [PMID: 33178271 DOI: 10.1155/2020/2319194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Wang J, Zhang Y, Pi J, Xing D, Wang C. Localized delivery of immunotherapeutics: A rising trend in the field. J Control Release 2021;340:149-67. [PMID: 34699871 DOI: 10.1016/j.jconrel.2021.10.013] [Reference Citation Analysis]
26 Weenink B, French PJ, Sillevis Smitt PAE, Debets R, Geurts M. Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers (Basel) 2020;12:E751. [PMID: 32235752 DOI: 10.3390/cancers12030751] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
27 Sudarsanam H, Buhmann R, Henschler R. Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Front Bioeng Biotechnol 2022;10:886637. [DOI: 10.3389/fbioe.2022.886637] [Reference Citation Analysis]
28 Skorka K, Ostapinska K, Malesa A, Giannopoulos K. The Application of CAR-T Cells in Haematological Malignancies. Arch Immunol Ther Exp (Warsz) 2020;68:34. [PMID: 33156409 DOI: 10.1007/s00005-020-00599-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kabir TF, Kunos CA, Villano JL, Chauhan A. Immunotherapy for Medulloblastoma: Current Perspectives. Immunotargets Ther 2020;9:57-77. [PMID: 32368525 DOI: 10.2147/ITT.S198162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
30 Labbé RP, Vessillier S, Rafiq QA. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses 2021;13:1528. [PMID: 34452392 DOI: 10.3390/v13081528] [Reference Citation Analysis]
31 Belderbos RA, Vroman H, Aerts JGJV. Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma. Front Oncol 2020;10:777. [PMID: 32582537 DOI: 10.3389/fonc.2020.00777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife 2020;9:e52176. [PMID: 32014107 DOI: 10.7554/eLife.52176] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
33 Singh AP, Zheng X, Lin-Schmidt X, Chen W, Carpenter TJ, Zong A, Wang W, Heald DL. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. MAbs 2020;12:1688616. [PMID: 31852337 DOI: 10.1080/19420862.2019.1688616] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
34 Voskamp MJ, Li S, van Daalen KR, Crnko S, Ten Broeke T, Bovenschen N. Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. Cancers (Basel) 2021;13:5387. [PMID: 34771550 DOI: 10.3390/cancers13215387] [Reference Citation Analysis]
35 Hong B, Dong R. Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review. Transl Cancer Res 2021;10:1559-67. [PMID: 35116480 DOI: 10.21037/tcr-20-3302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Yu YD, Kim TJ. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review. Int J Mol Sci 2021;22:E640. [PMID: 33440664 DOI: 10.3390/ijms22020640] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Hormuth DA 2nd, Farhat M, Christenson C, Curl B, Chad Quarles C, Chung C, Yankeelov TE. Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy. Adv Drug Deliv Rev 2022;187:114367. [PMID: 35654212 DOI: 10.1016/j.addr.2022.114367] [Reference Citation Analysis]
38 Jenkins Y, Zabkiewicz J, Ottmann O, Jones N. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy. Antibodies (Basel) 2021;10:17. [PMID: 33925949 DOI: 10.3390/antib10020017] [Reference Citation Analysis]
39 Pinte L, Cunningham A, Trébéden-Negre H, Nikiforow S, Ritz J. Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol 2020;11:608485. [PMID: 33658994 DOI: 10.3389/fimmu.2020.608485] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Cong W, Shi Y, Qi Y, Wu J, Gong L, He M. Viral approaches to study the mammalian brain: Lineage tracing, circuit dissection and therapeutic applications. J Neurosci Methods 2020;335:108629. [PMID: 32045571 DOI: 10.1016/j.jneumeth.2020.108629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Schepisi G, Casadei C, Toma I, Poti G, Iaia ML, Farolfi A, Conteduca V, Lolli C, Ravaglia G, Brighi N, Altavilla A, Martinelli G, De Giorgi U. Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. Cancers (Basel) 2021;13:840. [PMID: 33671294 DOI: 10.3390/cancers13040840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Del Vecchio C, Calistri A, Parolin C, Mucignat-Caretta C. Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma. Cancers (Basel) 2019;11:E417. [PMID: 30909628 DOI: 10.3390/cancers11030417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]